Literature DB >> 25326577

Emerging molecular phenotypes of asthma.

Anuradha Ray1, Timothy B Oriss1, Sally E Wenzel2.   

Abstract

Although asthma has long been considered a heterogeneous disease, attempts to define subgroups of asthma have been limited. In recent years, both clinical and statistical approaches have been utilized to better merge clinical characteristics, biology, and genetics. These combined characteristics have been used to define phenotypes of asthma, the observable characteristics of a patient determined by the interaction of genes and environment. Identification of consistent clinical phenotypes has now been reported across studies. Now the addition of various 'omics and identification of specific molecular pathways have moved the concept of clinical phenotypes toward the concept of molecular phenotypes. The importance of these molecular phenotypes is being confirmed through the integration of molecularly targeted biological therapies. Thus the global term asthma is poised to become obsolete, being replaced by terms that more specifically identify the pathology associated with the disease.
Copyright © 2015 the American Physiological Society.

Entities:  

Keywords:  Type 2; asthma; endotypes; molecular; phenotypes

Mesh:

Substances:

Year:  2014        PMID: 25326577      PMCID: PMC4338947          DOI: 10.1152/ajplung.00070.2014

Source DB:  PubMed          Journal:  Am J Physiol Lung Cell Mol Physiol        ISSN: 1040-0605            Impact factor:   5.464


  117 in total

1.  Non-eosinophilic corticosteroid unresponsive asthma.

Authors:  I D Pavord; C E Brightling; G Woltmann; A J Wardlaw
Journal:  Lancet       Date:  1999-06-26       Impact factor: 79.321

2.  T-helper type 2-driven inflammation defines major subphenotypes of asthma.

Authors:  Prescott G Woodruff; Barmak Modrek; David F Choy; Guiquan Jia; Alexander R Abbas; Almut Ellwanger; Laura L Koth; Joseph R Arron; John V Fahy
Journal:  Am J Respir Crit Care Med       Date:  2009-05-29       Impact factor: 21.405

3.  T(H)17-associated cytokines (IL-17A and IL-17F) in severe asthma.

Authors:  Wisam Al-Ramli; David Préfontaine; Fazila Chouiali; James G Martin; Ron Olivenstein; Catherine Lemière; Qutayba Hamid
Journal:  J Allergy Clin Immunol       Date:  2009-04-10       Impact factor: 10.793

Review 4.  Innate immune cells in asthma.

Authors:  Julie Deckers; Filipe Branco Madeira; Hamida Hammad
Journal:  Trends Immunol       Date:  2013-09-12       Impact factor: 16.687

5.  Randomized, double-blind, placebo-controlled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma.

Authors:  William W Busse; Stephen Holgate; Edward Kerwin; Yun Chon; Jingyuan Feng; Joseph Lin; Shao-Lee Lin
Journal:  Am J Respir Crit Care Med       Date:  2013-12-01       Impact factor: 21.405

6.  Inhibition of allergic inflammation in a murine model of asthma by expression of a dominant-negative mutant of GATA-3.

Authors:  D H Zhang; L Yang; L Cohn; L Parkyn; R Homer; P Ray; A Ray
Journal:  Immunity       Date:  1999-10       Impact factor: 31.745

7.  Characterization of factors associated with systemic corticosteroid use in severe asthma: data from the Severe Asthma Research Program.

Authors:  Kenneth Wysocki; Seo Young Park; Eugene Bleecker; William Busse; Mario Castro; Kian Fan Chung; Benjamin Gaston; Serpil Erzurum; Elliot Israel; W Gerald Teague; Charity G Moore; Sally Wenzel
Journal:  J Allergy Clin Immunol       Date:  2013-12-09       Impact factor: 10.793

8.  Treatment of allergic airway inflammation and hyperresponsiveness by antisense-induced local blockade of GATA-3 expression.

Authors:  S Finotto; G T De Sanctis; H A Lehr; U Herz; M Buerke; M Schipp; B Bartsch; R Atreya; E Schmitt; P R Galle; H Renz; M F Neurath
Journal:  J Exp Med       Date:  2001-06-04       Impact factor: 14.307

9.  Independent cellular processes for hippocampal memory consolidation and reconsolidation.

Authors:  Jonathan L C Lee; Barry J Everitt; Kerrie L Thomas
Journal:  Science       Date:  2004-04-08       Impact factor: 47.728

10.  Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma.

Authors:  Elisabeth H Bel; Sally E Wenzel; Philip J Thompson; Charlene M Prazma; Oliver N Keene; Steven W Yancey; Hector G Ortega; Ian D Pavord
Journal:  N Engl J Med       Date:  2014-09-08       Impact factor: 91.245

View more
  37 in total

Review 1.  Innovations in asthma therapy: is there a role for inhaled statins?

Authors:  Amir A Zeki; Mona Elbadawi-Sidhu
Journal:  Expert Rev Respir Med       Date:  2018-05-03       Impact factor: 3.772

Review 2.  Update on the role of endoplasmic reticulum stress in asthma.

Authors:  Kang Miao; Lei Zhang; Ting Pan; Yi Wang
Journal:  Am J Transl Res       Date:  2020-04-15       Impact factor: 4.060

3.  Overcoming Translational Barriers in Acute Kidney Injury: A Report from an NIDDK Workshop.

Authors:  Anna Zuk; Paul M Palevsky; Linda Fried; Frank E Harrell; Samina Khan; Dianne B McKay; Luke Devey; Lakhmir Chawla; Mark de Caestecker; James S Kaufman; B Taylor Thompson; Anupam Agarwal; Tom Greene; Mark Douglas Okusa; Joseph V Bonventre; Laura M Dember; Kathleen D Liu; Benjamin D Humphreys; Daniel Gossett; Yining Xie; Jenna M Norton; Paul L Kimmel; Robert A Star
Journal:  Clin J Am Soc Nephrol       Date:  2018-03-09       Impact factor: 8.237

Review 4.  Revisiting the NIH Taskforce on the Research needs of Eosinophil-Associated Diseases (RE-TREAD).

Authors:  Paneez Khoury; Praveen Akuthota; Steven J Ackerman; Joseph R Arron; Bruce S Bochner; Margaret H Collins; Jean-Emmanuel Kahn; Patricia C Fulkerson; Gerald J Gleich; Rashmi Gopal-Srivastava; Elizabeth A Jacobsen; Kristen M Leiferman; Levi-Schaffer Francesca; Sameer K Mathur; Michael Minnicozzi; Calman Prussin; Marc E Rothenberg; Florence Roufosse; Kathleen Sable; Dagmar Simon; Hans-Uwe Simon; Lisa A Spencer; Jonathan Steinfeld; Andrew J Wardlaw; Michael E Wechsler; Peter F Weller; Amy D Klion
Journal:  J Leukoc Biol       Date:  2018-04-19       Impact factor: 4.962

Review 5.  Targeting Interleukin-5 or Interleukin-5Rα: Safety Considerations.

Authors:  Diego Bagnasco; Matteo Ferrando; Marco Caminati; Alice Bragantini; Francesca Puggioni; Gilda Varricchi; Giovanni Passalacqua; Giorgio Walter Canonica
Journal:  Drug Saf       Date:  2017-07       Impact factor: 5.606

Review 6.  Evolving Concepts of Asthma.

Authors:  Marc Gauthier; Anuradha Ray; Sally E Wenzel
Journal:  Am J Respir Crit Care Med       Date:  2015-09-15       Impact factor: 21.405

7.  IRF5 distinguishes severe asthma in humans and drives Th1 phenotype and airway hyperreactivity in mice.

Authors:  Timothy B Oriss; Mahesh Raundhal; Christina Morse; Rachael E Huff; Sudipta Das; Rachel Hannum; Marc C Gauthier; Kathryn L Scholl; Krishnendu Chakraborty; Seyed M Nouraie; Sally E Wenzel; Prabir Ray; Anuradha Ray
Journal:  JCI Insight       Date:  2017-05-18

Review 8.  Current concepts of severe asthma.

Authors:  Anuradha Ray; Mahesh Raundhal; Timothy B Oriss; Prabir Ray; Sally E Wenzel
Journal:  J Clin Invest       Date:  2016-07-01       Impact factor: 14.808

Review 9.  New and emerging therapies for asthma.

Authors:  Alexander S Kim; Taylor A Doherty
Journal:  Ann Allergy Asthma Immunol       Date:  2016-01       Impact factor: 6.347

10.  Severe asthma in humans and mouse model suggests a CXCL10 signature underlies corticosteroid-resistant Th1 bias.

Authors:  Marc Gauthier; Krishnendu Chakraborty; Timothy B Oriss; Mahesh Raundhal; Sudipta Das; Jie Chen; Rachael Huff; Ayan Sinha; Merritt Fajt; Prabir Ray; Sally E Wenzel; Anuradha Ray
Journal:  JCI Insight       Date:  2017-07-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.